• 1
    Hooper WC, Evatt BL. The role of activated protein C resistance in the pathogenesis of venous thrombosis. Am J Med Sci 1998; 316: 1208.
  • 2
    Heit JA, Cohen AT, Anderson FA Jr, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 910.
  • 3
    Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120: 196471.
  • 4
    ACCP/NHLBI National Conference on Antithrombotic Therapy. American College of Chest Physicians and the National Heart, Lung and Blood Institute. Chest 1986; 89(2 Suppl): 1S106S.
  • 5
    Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793800.
  • 6
    Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 8749.
  • 7
    Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 3259.
  • 8
    Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119 (1 Suppl.): 132S75S.
  • 9
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 3(Suppl.): 338S400S.
  • 10
    Vallano A, Arnau JM, Miralda GP, Perez-Bartoli J. Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thromb J 2004; 2: 3.
  • 11
    Aujesky D, Guignard E, Pannatier A, Cornuz J. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med 2002; 17: 78891.
  • 12
    Tapson VF, Decousus H, Piovella F, Zotz AB, Allegrone J, Anderson FA, for the IMPROVE Investigators. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). Blood (ASH Annual Meeting Abstracts) 2003; 102: Abstract 1154.
  • 13
    Goldhaber SZ, Tapson VF. DVT Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 25962.
  • 14
    Tapson VF, Hyers TM, Waldo AL, Ballard DJ, Becker RC, Caprini JA, Khetan R, Wittkowsky AK, Colgan KJ, Shillington AC. NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165: 145864.
  • 15
    United States Department of Health and Human Services. Office for Civil Rights. HIPAA. Medical Privacy – National Standards to Protect the Privacy of Personal Health Information.; accessed 1 February 2007.
  • 16
    United States Department of Health and Human Services. Policy for Protection of Human Research Subjects.; accessed 1 February 2007.
  • 17
    McGarry LJ, Thompson D. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely ill medical inpatients in community practice. Clin Ther 2004; 26: 41930.
  • 18
    Stinnett JM, Pendleton R, Skordos L, Wheeler M, Rodgers GM. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005; 78: 16772.
  • 19
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med 2000; 160: 80915.
  • 20
    Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 145865.
  • 21
    Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107(Suppl. 1): I2230.
  • 22
    Dhond AJ, Michelena HI, Ezekowitz MD. Anticoagulation in the elderly. Am J Geriatr Cardiol 2003; 12: 24350.
  • 23
    Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 96977.
  • 24
    Chyna JT. Preparing for DVT core measures. Healthcare leaders should begin preparing for new deep vein thrombosis prevention standards. Healthc Exec 2005; 20: 667.